Nature Cancer

Papers
(The H4-Index of Nature Cancer is 75. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Untangling the threads of immunotherapy research604
Outcompeting neighbors for intestinal cancer initiation398
Gut decisions in CAR T cell therapy376
Alzheimer’s drug turns macrophages against cancer373
PARP11 interfer(on)es with CAR T cell efficacy317
Enhancing childhood cancer targetability311
Shooting for multiplexed pathology with Orion301
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling295
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction269
A macrophage-activated abscopal effect238
Breaking frontiers with multidisciplinary cancer research226
MALAT1 protects dormant tumor cells from immune elimination206
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity203
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma198
Considering molecular alterations as pan-cancer tissue-agnostic targets194
A low-coverage liquid biopsy for lung cancer194
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma192
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages192
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC186
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80163
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung152
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling152
An oncolytic circular RNA therapy144
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms133
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial130
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer127
The cGAS–STING pathway and cancer125
Expanding the options for KRAS inhibition124
The importance of being generous123
DePICting T cell–APC crosstalk in cancer117
Reflecting on the golden age of cancer research117
Beating cancer one carbon at a time116
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss112
Advancing therapeutics in small-cell lung cancer110
Determinants of resistance and response to melanoma therapy109
Bone marrow progenitor-like cells against leukemia cure108
Shaping the microenvironment in peritoneal metastases106
Palmitate oxidation drives a pro-metastatic post-translational modification106
Stress granules shape metabolic reprogramming and drug resistance105
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors103
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma98
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor95
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity94
Impact of context-dependent autophagy states on tumor progression93
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia92
The labors of referees92
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy92
Cycling back to folate metabolism in cancer91
Thriving in diverse ecosystems91
A quick guide for clinical oncology87
Sex-specific gut microbiota and neutrophil senescence in bladder cancer84
Inflammation meets translation in AML84
Antibody avidity meets multiple myeloma84
Sarcoma ecotypes determine immunotherapy benefit84
LAG-3 and PD-1 blockade raises the bar for melanoma83
Innate immunity drives epithelial cell plasticity during prostate tumor formation83
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma83
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes82
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms81
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers81
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer81
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling80
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis80
A comeback for checkpoint inhibition in multiple myeloma80
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic80
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer79
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia79
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial78
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas78
Radioligand cancer therapy comes to the fore76
Radiation sparks a dark side in neutrophils76
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis76
Bispecific antibodies seek out colon cancer stem cells76
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors76
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity76
Building a translational cancer dependency map for The Cancer Genome Atlas75
0.2548348903656